世界首例抗衰老药将临床试验 或让人活到120岁

2016-06-07 佚名 参考消息网

英媒称,世界首例抗衰老药将于明年进行临床试验,试验结果可能让阿尔茨海默症和帕金森病等疾病成为遥远的回忆。 英国《每日电讯报》网站12月1日报道称,科学家现在相信,延缓人的衰老速度并让他们健康活到110多岁、甚至120多岁是有可能的。 尽管这听起来或许像科幻小说,但研究人员已证明,用于治疗糖尿病的二甲双胍可以延长动物的寿命。美国食品和药物管理局现在已批准该项临床试验,以验证这种药物是否能对人产生

英媒称,世界首例抗衰老药将于明年进行临床试验,试验结果可能让阿尔茨海默症和帕金森病等疾病成为遥远的回忆。

英国《每日电讯报》网站12月1日报道称,科学家现在相信,延缓人的衰老速度并让他们健康活到110多岁、甚至120多岁是有可能的。

尽管这听起来或许像科幻小说,但研究人员已证明,用于治疗糖尿病二甲双胍可以延长动物的寿命。美国食品和药物管理局现在已批准该项临床试验,以验证这种药物是否能对人产生同样的效果。

如果试验成功,则意味着70多岁的老者从生物学角度而言将和50多岁的人一样健康。这可能会为老年学开启一个新时代。届时医生将不必再分别治疗癌症、糖尿病和痴呆症,而只需针对衰老这一根本的机制进行治疗。

苏格兰抗衰老专家、就职于美国加利福尼亚的巴克老龄化问题研究所的戈登·利思戈教授是上述研究的顾问之一。他说:“如果你把衰老过程作为研究对象,并且延缓了衰老,那么你就同样延缓了所有与衰老相关的疾病。这是革命性的,是前所未有的。”

衰老并非生命所不可避免的组成部分,因为所有细胞内都含有一种可让机体永远正常工作的DNA蓝图。有些海洋生物根本就不会衰老。

但在我们的一生中,必须要经历数十亿次的细胞分裂,才能维持机体的正常运转。而细胞分裂次数越多,就会有更多的错误潜入这一进程。随着细胞问题的增多,机体最终将无法对损伤进行修复。以癌症为例,细胞不再有能力摆脱突变,肿瘤也就不断发展。再以阿尔茨海默症为例,大脑一旦停止清理淀粉样斑块,人随后便会出现痴呆症状。

科学家认为,最好的抗衰老候选药物是二甲双胍。它是世界上应用最广泛的降糖药,服用它每天仅需花费10便士(约合15美分)。

二甲双胍能增加向细胞中释放的氧分子数量,这似乎能增加机体的强健程度并延长寿命。

当比利时研究人员在秀丽隐杆线虫身上进行二甲双胍测试时,这些线虫不仅衰老速度变慢,而且保持更健康状态的时间也变长了。它们的活动速度没有减慢,也没有长出皱纹。对老鼠使用二甲双胍后,它们的寿命延长了近40%,骨骼也变得更结实。去年,英国加的夫大学发现,糖尿病患者服用二甲双胍后,他们事实上比非糖尿病患者的寿命更长,尽管理论上糖尿病应该让他们平均减寿8年。

这项名为“用二甲双胍对抗衰老”的临床试验计划于明年冬天在美国开始。目前,来自多家机构的科学家正在筹集资金并招募3000名年龄在70岁到80岁之间、患有或今后有可能患有癌症、心脏病和痴呆症的老年人。他们期待能借此证明,二甲双胍能延缓衰老并阻止疾病的发生与发展。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1968441, encodeId=46541968441bc, content=<a href='/topic/show?id=a57f208660f' target=_blank style='color:#2F92EE;'>#世界首例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20866, encryptionId=a57f208660f, topicName=世界首例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jan 18 20:26:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129095, encodeId=76201290955b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Sep 17 08:20:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122329, encodeId=c3e212232938, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 10:02:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119404, encodeId=f31711940467, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 10 15:42:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92605, encodeId=c6259260551, content=120岁,估计到时候**率就明显高了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 19:30:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89019, encodeId=32f58901904, content=确实看到了一丝希望,但得做好最坏打算。, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/4A00E77B913D12376371C3D34B9E6937/100, createdBy=23961732752, createdName=QQ3821412e, createdTime=Wed Jun 08 09:02:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88962, encodeId=002288962aa, content=副作用是什么?_?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Jun 07 16:52:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88958, encodeId=d61188958bc, content=这个可喜可忧, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3781729882, createdName=WEIXINa82df6bc, createdTime=Tue Jun 07 16:15:00 CST 2016, time=2016-06-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1968441, encodeId=46541968441bc, content=<a href='/topic/show?id=a57f208660f' target=_blank style='color:#2F92EE;'>#世界首例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20866, encryptionId=a57f208660f, topicName=世界首例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jan 18 20:26:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129095, encodeId=76201290955b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Sep 17 08:20:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122329, encodeId=c3e212232938, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 10:02:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119404, encodeId=f31711940467, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 10 15:42:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92605, encodeId=c6259260551, content=120岁,估计到时候**率就明显高了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 19:30:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89019, encodeId=32f58901904, content=确实看到了一丝希望,但得做好最坏打算。, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/4A00E77B913D12376371C3D34B9E6937/100, createdBy=23961732752, createdName=QQ3821412e, createdTime=Wed Jun 08 09:02:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88962, encodeId=002288962aa, content=副作用是什么?_?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Jun 07 16:52:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88958, encodeId=d61188958bc, content=这个可喜可忧, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3781729882, createdName=WEIXINa82df6bc, createdTime=Tue Jun 07 16:15:00 CST 2016, time=2016-06-07, status=1, ipAttribution=)]
    2016-09-17 ylzr123

    赞一个!好文章拜读了,认真学习了。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1968441, encodeId=46541968441bc, content=<a href='/topic/show?id=a57f208660f' target=_blank style='color:#2F92EE;'>#世界首例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20866, encryptionId=a57f208660f, topicName=世界首例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jan 18 20:26:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129095, encodeId=76201290955b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Sep 17 08:20:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122329, encodeId=c3e212232938, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 10:02:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119404, encodeId=f31711940467, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 10 15:42:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92605, encodeId=c6259260551, content=120岁,估计到时候**率就明显高了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 19:30:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89019, encodeId=32f58901904, content=确实看到了一丝希望,但得做好最坏打算。, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/4A00E77B913D12376371C3D34B9E6937/100, createdBy=23961732752, createdName=QQ3821412e, createdTime=Wed Jun 08 09:02:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88962, encodeId=002288962aa, content=副作用是什么?_?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Jun 07 16:52:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88958, encodeId=d61188958bc, content=这个可喜可忧, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3781729882, createdName=WEIXINa82df6bc, createdTime=Tue Jun 07 16:15:00 CST 2016, time=2016-06-07, status=1, ipAttribution=)]
    2016-09-11 1e10c84am36(暂无匿称)

    己拜读,受益匪浅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1968441, encodeId=46541968441bc, content=<a href='/topic/show?id=a57f208660f' target=_blank style='color:#2F92EE;'>#世界首例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20866, encryptionId=a57f208660f, topicName=世界首例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jan 18 20:26:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129095, encodeId=76201290955b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Sep 17 08:20:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122329, encodeId=c3e212232938, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 10:02:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119404, encodeId=f31711940467, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 10 15:42:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92605, encodeId=c6259260551, content=120岁,估计到时候**率就明显高了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 19:30:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89019, encodeId=32f58901904, content=确实看到了一丝希望,但得做好最坏打算。, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/4A00E77B913D12376371C3D34B9E6937/100, createdBy=23961732752, createdName=QQ3821412e, createdTime=Wed Jun 08 09:02:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88962, encodeId=002288962aa, content=副作用是什么?_?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Jun 07 16:52:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88958, encodeId=d61188958bc, content=这个可喜可忧, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3781729882, createdName=WEIXINa82df6bc, createdTime=Tue Jun 07 16:15:00 CST 2016, time=2016-06-07, status=1, ipAttribution=)]
    2016-09-10 1e10c84am36(暂无匿称)

    好文章,百姓也能从中学到好多医学知识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1968441, encodeId=46541968441bc, content=<a href='/topic/show?id=a57f208660f' target=_blank style='color:#2F92EE;'>#世界首例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20866, encryptionId=a57f208660f, topicName=世界首例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jan 18 20:26:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129095, encodeId=76201290955b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Sep 17 08:20:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122329, encodeId=c3e212232938, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 10:02:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119404, encodeId=f31711940467, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 10 15:42:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92605, encodeId=c6259260551, content=120岁,估计到时候**率就明显高了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 19:30:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89019, encodeId=32f58901904, content=确实看到了一丝希望,但得做好最坏打算。, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/4A00E77B913D12376371C3D34B9E6937/100, createdBy=23961732752, createdName=QQ3821412e, createdTime=Wed Jun 08 09:02:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88962, encodeId=002288962aa, content=副作用是什么?_?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Jun 07 16:52:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88958, encodeId=d61188958bc, content=这个可喜可忧, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3781729882, createdName=WEIXINa82df6bc, createdTime=Tue Jun 07 16:15:00 CST 2016, time=2016-06-07, status=1, ipAttribution=)]
    2016-07-10 oo902

    120岁,估计到时候**率就明显高了吧

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1968441, encodeId=46541968441bc, content=<a href='/topic/show?id=a57f208660f' target=_blank style='color:#2F92EE;'>#世界首例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20866, encryptionId=a57f208660f, topicName=世界首例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jan 18 20:26:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129095, encodeId=76201290955b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Sep 17 08:20:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122329, encodeId=c3e212232938, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 10:02:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119404, encodeId=f31711940467, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 10 15:42:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92605, encodeId=c6259260551, content=120岁,估计到时候**率就明显高了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 19:30:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89019, encodeId=32f58901904, content=确实看到了一丝希望,但得做好最坏打算。, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/4A00E77B913D12376371C3D34B9E6937/100, createdBy=23961732752, createdName=QQ3821412e, createdTime=Wed Jun 08 09:02:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88962, encodeId=002288962aa, content=副作用是什么?_?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Jun 07 16:52:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88958, encodeId=d61188958bc, content=这个可喜可忧, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3781729882, createdName=WEIXINa82df6bc, createdTime=Tue Jun 07 16:15:00 CST 2016, time=2016-06-07, status=1, ipAttribution=)]
    2016-06-08 QQ3821412e

    确实看到了一丝希望,但得做好最坏打算。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1968441, encodeId=46541968441bc, content=<a href='/topic/show?id=a57f208660f' target=_blank style='color:#2F92EE;'>#世界首例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20866, encryptionId=a57f208660f, topicName=世界首例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jan 18 20:26:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129095, encodeId=76201290955b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Sep 17 08:20:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122329, encodeId=c3e212232938, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 10:02:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119404, encodeId=f31711940467, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 10 15:42:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92605, encodeId=c6259260551, content=120岁,估计到时候**率就明显高了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 19:30:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89019, encodeId=32f58901904, content=确实看到了一丝希望,但得做好最坏打算。, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/4A00E77B913D12376371C3D34B9E6937/100, createdBy=23961732752, createdName=QQ3821412e, createdTime=Wed Jun 08 09:02:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88962, encodeId=002288962aa, content=副作用是什么?_?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Jun 07 16:52:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88958, encodeId=d61188958bc, content=这个可喜可忧, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3781729882, createdName=WEIXINa82df6bc, createdTime=Tue Jun 07 16:15:00 CST 2016, time=2016-06-07, status=1, ipAttribution=)]
    2016-06-07 lyh994

    副作用是什么?_?

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1968441, encodeId=46541968441bc, content=<a href='/topic/show?id=a57f208660f' target=_blank style='color:#2F92EE;'>#世界首例#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20866, encryptionId=a57f208660f, topicName=世界首例)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Wed Jan 18 20:26:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129095, encodeId=76201290955b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Sep 17 08:20:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122329, encodeId=c3e212232938, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 10:02:00 CST 2016, time=2016-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=119404, encodeId=f31711940467, content=好文章,百姓也能从中学到好多医学知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 10 15:42:00 CST 2016, time=2016-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92605, encodeId=c6259260551, content=120岁,估计到时候**率就明显高了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Sun Jul 10 19:30:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=89019, encodeId=32f58901904, content=确实看到了一丝希望,但得做好最坏打算。, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/1103841572/4A00E77B913D12376371C3D34B9E6937/100, createdBy=23961732752, createdName=QQ3821412e, createdTime=Wed Jun 08 09:02:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88962, encodeId=002288962aa, content=副作用是什么?_?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Tue Jun 07 16:52:00 CST 2016, time=2016-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88958, encodeId=d61188958bc, content=这个可喜可忧, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3781729882, createdName=WEIXINa82df6bc, createdTime=Tue Jun 07 16:15:00 CST 2016, time=2016-06-07, status=1, ipAttribution=)]
    2016-06-07 WEIXINa82df6bc

    这个可喜可忧

    0

相关资讯

J Acq Immun Def Synd:Dolutegravir对二甲双胍药代动力学的影响研究

近期发表在J Acquir Immune Defic Syndr的研究称,正在开始或将要停用Dolutegravir的患者为保持最佳血糖控制应考虑调整二甲双胍剂量。Dolutegravir是抗艾滋病毒药物中的整合酶链转移抑制剂,为OCT2转运体蛋白抑制剂;而二甲双胍是OCT2底物。研究者进行了一项非盲三期交叉研究,探究同时服用Dolutegravir和二甲双胍时,Dolutegravir对二甲双胍

NEJM:二甲双胍可减少无糖尿病的肥胖妊娠女性的体重增加

肥胖与不良妊娠结局的风险增加相关。生活方式干预研究并没有显示出改善的结果。在妊娠期糖尿病患者中,二甲双胍改善胰岛素敏感性,与那些不服用二甲双胍的患者相比,体重增加减少。原始出处:Argyro Syngelaki,Kypros H. Nicolaides,Jyoti Balani,et al.Metformin versus Placebo in Obese Pregnant Women witho

BMJ研究新闻:二甲双胍——2型糖尿病治疗的一线药物

来自马里兰州巴尔的摩的约翰霍普金斯大学医学院的一项全面的系统回顾和荟萃分析表明,使用二甲双胍治疗2型糖尿病可改善机体的糖化血红蛋白、体重和心血管疾病死亡率,因此支持二甲双胍作为2型糖尿病治疗的一线药物,该研究结果已在线发表于Annals of Internal Medicine。

ASCO 2016 :糖尿病药物二甲双胍或可有效预防并治疗乳腺癌

近日,一项发表于美国临床肿瘤学会年会上的研究报告中,来自宾夕法尼亚大学的研究人员通过研究发现,常用作2型糖尿病一线疗法的药物二甲双胍或可改善某些乳腺癌患者的生存,同时其还可作为治疗子宫内膜增生症患者的潜在疗法。 在其中一项研究中,研究人员首先检测了二甲双胍的治疗对乳腺癌患者生存率的影响,研究者对在1997年至2013年间诊断为乳腺癌或者进行手术疗法的1215名患者进行了相应的临床试验并且检测

Cell Rep:二甲双胍降糖机制有新发现

梅奥诊所的研究表明实验室发现并不能整个讲述糖尿病药物二甲双胍如何限制血液中葡萄糖水平。研究人员发现二甲双胍并不限制激素胰高血糖素的功能,特别是胰高血糖素刺激肝生产葡萄糖。这篇文章发表在 Cell Reports杂志上。“在我们的临床试验中,二甲双胍治疗似乎触发补偿胰高血糖素增加,可以缓和糖尿病前期的个体中二甲双胍降低葡萄糖的生产,防止低血糖的可能性,”医学博士,梅奥诊所内分泌学家和文章的

JCEM:长期应用二甲双胍与维生素B12缺乏相关(DPPOS研究)?

来自纽约阿尔伯特 ·爱因斯坦医学院的Crandall JP博士和同事对糖尿病预防计划(DPP)和糖尿病预防计划结果研究(Diabetes Prevention Program Research Group,DPPOS)中1073 名接受二甲双胍治疗和1082名接受安慰剂的参与者3.2 年的随访数据进行分析,以确定长期应用二甲双胍对维生素B12的影响。随后,参与者再次接受9年的非盲二甲双胍